Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.09% | 7.52% | 37.67% | -55.27% | -56.59% |
| Total Depreciation and Amortization | -1.79% | -0.33% | 0.79% | 1.21% | 2.15% |
| Total Amortization of Deferred Charges | 20.80% | 13.61% | 13.61% | 13.61% | 13.61% |
| Total Other Non-Cash Items | 128.23% | 573.09% | 140.29% | 520.33% | 343.60% |
| Change in Net Operating Assets | 80.65% | 102.20% | -602.82% | -1,940.43% | -621.17% |
| Cash from Operations | 41.43% | 40.16% | -15.84% | -25.61% | -31.23% |
| Capital Expenditure | -8.34% | -9.35% | -19.53% | -18.47% | -16.34% |
| Sale of Property, Plant, and Equipment | -99.13% | -99.52% | -96.77% | 740.27% | 719.48% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 281.63% | 211.03% | 197.88% | 139.90% | 123.85% |
| Other Investing Activities | 29.84% | 69.17% | 74.08% | 72.72% | 37.05% |
| Cash from Investing | 27.02% | 56.63% | 59.47% | 59.40% | 28.17% |
| Total Debt Issued | 179.03% | 106.36% | 254.30% | 107.58% | 227.83% |
| Total Debt Repaid | -263.86% | -154.68% | -18.12% | 27.60% | 6.14% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -2,129.58% | 19.09% | 19.09% | 19.09% | 91.36% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 2.38% | 3.33% | 3.14% | 3.95% | 2.69% |
| Other Financing Activities | -24.60% | -39.09% | -13.84% | 86.91% | 43.59% |
| Cash from Financing | -103.83% | -61.57% | 105.19% | 100.04% | 52.68% |
| Foreign Exchange rate Adjustments | -145.49% | -55.10% | -283.62% | 67.89% | 4.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 147.92% | -166.67% |
| Net Change in Cash | 17.97% | 145.91% | 200.37% | 230.94% | 73.94% |